Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study

Cover Page

Cite item

Full Text

Abstract

Background. PARP inhibitor olaparib shows encouraging results in the treatment of patients with BRCA-associated tumors. The detection of new tumors associated with abnormalities of the BRCA gene, also can lead to the expansion of PARP inhibitors application. The application of PARP inhibitors improved treatment outcomes for ovarian, breast, prostate and pancreatic cancers in comparison with standard drug therapy regimens, demonstrating the moderate toxicity profile. All this makes olaparib the significant option in planning the tactics of treatment of this category of patients.

Aim. Assess the efficacy of olaparib in real clinical practice conditions in our region and to demonstrate the clinical experience accumulated in the regional clinical oncology dispensary.

Materials and methods. We analyzed the cases of the treatment with olaparib in the Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Bashkortostan. The study included 79 patients.

Results. Median progression-free survival reached 12 months and the best response was the stabilization of the disease among patients receiving olaparib. Median progression-free survival was 6 months and the best response was the stabilization of the disease among the patients treated with olaparib during Re-Challenge regimen.

Conclusion. Olaparib applying in real clinical practice demonstrated satisfactory results.

About the authors

Alexander V. Sultanbaev

Republican Clinical Oncological Dispensary

Author for correspondence.
Email: rkodrb@yandex.ru
ORCID iD: 0000-0003-0996-5995

Cand. Sci. (Med.)

Russian Federation, Ufa

Konstantin V. Menshikov

Republican Clinical Oncological Dispensary; Bashkir State Medical University

Email: kmenshikov80@bk.ru
ORCID iD: 0000-0003-3734-2779

Cand. Sci. (Med.)

Russian Federation, Ufa; Ufa

Shamil I. Musin

Republican Clinical Oncological Dispensary

Email: rkodrb@yandex.ru
ORCID iD: 0000-0003-1185-977X

Cand. Sci. (Med.)

Russian Federation, Ufa

Ainur F. Nasretdinov

Republican Clinical Oncological Dispensary

Email: rkodrb@yandex.ru
ORCID iD: 0000-0001-8340-7962

onсologist

Russian Federation, Ufa

Alfiya A. Fatikhova

Republican Clinical Oncological Dispensary

Email: rkodrb@yandex.ru
ORCID iD: 0000-0001-7821-0188

оnсologist

Russian Federation, Ufa

Adel A. Izmailov

Republican Clinical Oncological Dispensary; Bashkir State Medical University

Email: izmailov75@mail.ru
ORCID iD: 0000-0002-8461-9243

D. Sci. (Med.)

Russian Federation, Ufa; Ufa

Oleg N. Lipatov

Bashkir State Medical University

Email: lipatovoleg@bk.ru
ORCID iD: 0000-0002-8867-504X

D. Sci. (Med.)

Russian Federation, Ufa

Rustam T. Ayupov

Republican Clinical Oncological Dispensary

Email: ru2003@bk.ru
ORCID iD: 0000-0002-6769-7194

Cand. Sci. (Med.)

Russian Federation, Ufa

Nadezda I. Sultanbaeva

Republican Clinical Oncological Dispensary

Email: nd.sultan@rambler.ru
ORCID iD: 0000-0001-5926-0446

onсologist

Russian Federation, Ufa

Irina A. Menshikova

Bashkir State Medical University

Email: menshikova@bk.ru
ORCID iD: 0000-0002-8665-8895

Cand. Sci. (Med.)

Russian Federation, Ufa

Grigorii A. Serebrennikov

Bashkir State Medical University

Email: g.serebrennikov@mail.ru
ORCID iD: 0000-0002-7082-0085

Resident

Russian Federation, Ufa

References

  1. Baretta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis. Medicine (Baltimore). 2016;95(40):e4975. doi: 10.1097/MD.0000000000004975
  2. Sultanbaev AV, Lipatov O, Sultanbaeva N, et al. Germinal mutations landscape, which is responsible for cancer predisposition in multinational Republic of Bashkortostan. J Clin Oncol. 2021;39(15_suppl.):e22504-e22504. doi: 10.1200/JCO.2021.39.15_suppl.e22504
  3. Sultanbaev A, Menshikov K, Sultanbaeva N, et al. Organization of screening for prostate cancer in carriers of germinal mutations in the BRCA1/2 genes. Eur Urol Open Sci. 2020;21(15_suppl.):S59. doi: 10.1016/S2666-1683(20)36064-X
  4. Имянитов Е.Н. Наследственный рак молочной железы. Практичес- кая онкология. 2010;11(4):258-66 [Imyanitov EN. Hereditary breast cancer. Prakticheskaya onkologiya = Practical Oncology. 2010;11(4):258-66 (in Russian)].
  5. Имянитов Е.Н. Скрининг для лиц с наследственной предрасположеннос- тью к раку. Практическая онкология. 2010;11(2):101-8 [Imyanitov E.N. Skrining dlia lits s nasledstvennoi predraspolozhennost'iu k raku. Prakticheskaya onkologiya = Practical Oncology. 2010;11(2):101-8 (in Russian)].
  6. Имянитов Е.Н. Общие представления о наследственных опухолевых синдромах. Практическая онкология. 2014;15(3):101-6 [Imyanitov E.N. Obshchie predstavleniia o nasledstvennykh opukholevykh sindromakh. Prakticheskaya onkologiya = Practical Oncology. 2014;15(3):101-6 (in Russian)].
  7. Богомолова О.А., Шатова Ю.С., Верескунова М.И., и др. Герминальные мутации в генах BRCA1 и BRCA2 у пациенток юга России с клиническими приз- наками наследственного рака молочной железы. Современные проблемы науки и образования. 2017;5. Режим доступа: https://science-education.ru/ru/article/view?id=26920. Ссылка активна на 24.02.2022 [Bogomolova OA, Shatova IuS, Vereskunova MI et al. Germinal'nye mutatsii v genakh BRCA1 i BRCA2 u patsientok iuga Rossii s klinicheskimi priznakami nasledstvennogo raka molochnoi zhelezy. Sovremennye problemy nauki i obrazovaniia. 2017;5 (in Russian)].
  8. Sultanbaev AV, Menshikov K, Nasretdinov A, et al. Local features of germinal mutations incidence in cancer patients in the Republic of Bashkortostan. Ann Oncol. 2021;32(15_suppl.):S1367. doi: 10.1016/j.annonc.2021.08.2066
  9. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1
  10. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274-84. doi: 10.1016/S1470-2045(17)30469-2
  11. Robson M, Im S-A, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-33. doi: 10.1056/NEJMoa1706450
  12. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558-66. doi: 10.1093/annonc/mdz012
  13. Султанбаев А.В., Меньшиков К.В., Измайлов А.А., и др. BRCA-ассоциированный рак предстательной железы. BRCA-история одной семьи. Поволжский онкологический вестник. 2021;12(4):60-8 [Sultanbaev AV, Men'shikov KV, Izmailov AA, et al. BRCA-assotsiirovannyi rak predstatel'noi zhelezy. BRCA-istoriia odnoi sem'i. Povolzhskii onkologicheskii vestnik. 2021;12(4):60-8 (in Russian)].
  14. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-102. doi: 10.1056/NEJMoa1911440
  15. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-27. doi: 10.1056/NEJMoa1903387
  16. Essel KG, Behbakht K, Lai T, et al. PARPi after PARPi in epithelial ovarian cancer. Gynecol Oncol Reports. 2021;35(4):100699. doi: 10.1016/j.gore.2021.100699
  17. Pujade-Lauraine E, Selle F, Scambia G, et al. LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. Ann Oncol. 2021;32(4):S1308-9. doi: 10.1016/j.annonc.2021.08.2110

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Kaplan–Meier curve of progression-free survival (PFS) for patients applying olaparib.

Download (62KB)
Indexing metadata
3. Fig. 2. Kaplan–Meier curves of PFS for patients applying olaparib in different lines, log-rank p-value 0.001.

Download (84KB)
Indexing metadata
4. Fig. 3. Kaplan-Meier curve of PFS for patients applying olaparib as the Re-Challenge regimen.

Download (59KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies